Experienced in Menopause

Dr. Sarah M. Temkin

Gynecologic Oncology
1250 E Marshall St, Dept. Of Ob/gyn, 
Richmond, VA 
Experienced in Menopause
1250 E Marshall St, Dept. Of Ob/gyn, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sarah Temkin is a Gynecologic Oncologist in Richmond, Virginia. Dr. Temkin is rated as an Experienced provider by MediFind in the treatment of Menopause. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Oophorectomy.

Her clinical research consists of co-authoring 110 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Menopause.

Specialties
Gynecologic Oncology
Licenses
Obstetrics & Gynecology in VA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

1250 E Marshall St, Dept. Of Ob/gyn, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Nivolumab
Study Phase: Phase 2
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

110 Total Publications

To Improve Health in the United States, Focus on Women.
To Improve Health in the United States, Focus on Women.
Journal: JAMA
Published: September 17, 2025
Similar Doctors
Advanced in Menopause
Dr. Randal J. West
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Menopause
Dr. Randal J. West
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
1401 Johnston Willis Dr, Suite 1100, 
North Chesterfield, VA 
 (9.3 miles away)
804-323-5040
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Randal West is a Gynecologic Oncologist and an Oncologist in North Chesterfield, Virginia. Dr. West is rated as a Distinguished provider by MediFind in the treatment of Menopause. His top areas of expertise are Endometrial Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Oophorectomy, and Hysterectomy. Dr. West is currently accepting new patients.

Experienced in Menopause
Dr. Jaclyn A. Wall
Obstetrics and Gynecology | Gynecologic Oncology | Oncology
Experienced in Menopause
Dr. Jaclyn A. Wall
Obstetrics and Gynecology | Gynecologic Oncology | Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (1.9 miles away)
804-828-7929
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jaclyn Wall is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Richmond, Virginia. Dr. Wall is rated as an Advanced provider by MediFind in the treatment of Menopause. Her top areas of expertise are Ovarian Cancer, Eclampsia, Cervical Cancer, Menopause, and Intrauterine Device Insertion. Dr. Wall is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Temkin's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile